The finding of the INSPIRE trial, in which women with suspected preeclampsia were individually randomised to revealed or concealed sFlt-1/PlGF testing demonstrated similar results, that the clinical use of PlGF/sFlt-1 testing enabled more accurate admission rates of high-risk patients without changing admission rates overall, and improved identification of those with preeclampsia [21]. This evidence concerns the gene PGF and preeclampsia.